ADVFN - Advanced Financial Network.
HOME» NYSE » A » ABT Stock Price » ABT Stock News

Abbott Labs Share News

 Abbott Laboratories Stock Price
ABT Stock Price
 Abbott Laboratories Stock Chart
ABT Stock Chart
 Abbott Laboratories Stock News
ABT Stock News
 Abbott Laboratories Company Information
ABT Company Information
 Abbott Laboratories Stock Trades
ABT Stock Trades

Abbott Bid For US Approval Of New Use For Humira Is Delayed

By Peter Loftus Of DOW JONES NEWSWIRES Abbott Laboratories (ABT) has encountered a delay in its bid for U.S. regulatory approval to expand the uses of its blockbuster anti-inflammatory drug Humira to include treatment of the bowel disease ulcerative colitis. Abbott received a "complete response letter" from the U.S. Food and Drug Administration in late 2011 regarding Abbott's application to market Humira for colitis, spokeswoman Elizabeth Hoff said Monday. The FDA sends such letters when a drug application isn't yet ready for approval. The Abbott Park, Ill., company has provided additional information and continues to have a dialogue with the FDA, Hoff said. Abbott expects an agency decision by the end of this year, she said. She declined to provide contents of the complete response letter. Abbott filed for regulatory approval of Humira to treat ulcerative colitis in the U.S. and Europe in early 2011. The European Commission approved the new use in April. The regulatory applications were based on clinical data showing that Humira improved rates of disease remission versus a placebo in people with colitis, an inflammatory bowel disease that causes pain, diarrhea and other symptoms. Humira is currently approved in the U.S. to treat rheumatoid arthritis and several other inflammatory conditions. Abbott recorded $7.9 billion in Humira sales for 2011. -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581;

Stock News for Abbott Labs (ABT)
11/05/201514:41:24Quarterly Report (10-q)
11/03/201508:30:00Zoetis Lifts Outlook as Results Top Views
11/01/201511:23:035 Healthcare Trends to Invest in for the Next 20 Years
10/30/201512:31:00Health is a Marathon, not a Sprint
10/29/201515:52:00'Science' Says Abbott Is a Top Employer
10/28/201519:52:56Your One-Stop Dividend Aristocrat Resource
10/23/201502:04:49The Conservative Total Return Portfolio: 3 Hits And A Miss
10/22/201508:01:00Abbott fait équipe avec Cristiano Ronaldo, star du football...
10/22/201508:01:00Abbott Teams Up with Soccer Star Cristiano Ronaldo to Inspire...
10/22/201508:01:00Abbott Teams Up with Soccer Star Cristiano Ronaldo to Inspire...
10/21/201519:49:00Abbott Teams Up with Football Star Cristiano Ronaldo to Inspire...
10/21/201511:10:00Abbott Labs Profit Rises
10/21/201510:50:00Abbott Labs Profit Rises, Helped by Emerging Markets
10/21/201507:45:00Abbott Reports Third-Quarter 2015 Results
10/20/201517:30:59Notable earnings before Wednesday’s open
10/16/201501:40:00Valeant Probe Reprises Federal Focus on Drug Pricing
10/15/201510:00:00New York Road Runners and Abbott Partner for 2015 TCS New York...
10/12/201516:00:00Abbott Laboratories Dissolving Stent Shows Mixed Results
10/12/201515:57:00Abbott Laboratories Dissolving Stent Shows Mixed Results in Study
10/12/201514:25:00Abbott Announces Positive Clinical Results of Absorb™, the N...

Abbott Laboratories and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations